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ABSTRACT
Objective: Siddha system is an ancient traditional system of medicine treats many chronic ailments and neurological disorders. Muthu parpam is one 
of the herbo marine Siddha drugs which have the indication for neurocognitive dysfunction. The main objective of this current study was to evaluate 
the acetylcholine esterase (AChE) inhibition of Muthu parpam.
Methods: AChE activity was evaluated using a modified 96-well microplate assay based on Ellman’s method. Physostigmine (5, 10, 20, and 40 µg/ml) 
was used as the positive control.
Results: The result of this study clearly indicates that the test drug Muthu Parpam was effective in inhibiting AChE enzyme at the specified concentration 
dose dependently. Maximum percentage inhibition of about 71.68% was observed at 500 µg/ml when compared to that of the Physostigmine, a 
known AChE inhibitor with the maximum inhibition 84.87% at the concentration of 40 µg/ml.
Conclusion: Hence, this preliminary screening has proven the efficacy of Muthu parpam through AChE inhibition potential in the management of 
Alzheimer disease.
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INTRODUCTION
Alzheimer’s disease (AD) is characterized that occur during the formation 
of amyloid aggregates within the core of neuritic plaque, and therefore, 
the formation of intraneuronal neurofibrillary tangles within the brain 
of afflicted individuals [1]. In the human brain, there are two major 
forms of cholinesterases, namely, acetylcholine esterase (AChE) and 
butyrylcholinesterase [2]. The foremost remarkable biochemical change 
in AD patients may be reduced of ACh levels within the hippocampus 
and cortex of the brain [3]. ACh is the principal neurotransmitter which 
functions all told autonomic ganglia and is the only neurochemical 
that triggers motor division of the somatic systema nervosum. The 
deterioration of cholinergic neurons within the brain, and therefore, the 
loss of neurotransmission is the key causes of the decline in cognitive 
function in patients with AD [4]. In normal cholinergic activity consisting 
the sequence of release, binding and enzymatic deactivation of ACh by 
AChE, while abnormal cholinergic activity is characterized by a deficit or 
short-fall in cholinergic transmissions at synapses and has been attributed 
to reduced production of ACh or its excess deactivation/hydrolysis by 
AChE. Therefore, inhibition of AChE, the enzyme liable for the hydrolysis 
of ACh at the cholinergic synapse, is currently the foremost established 
approach to treating AD [5]. Impairment in signal transduction across 
synapses is the main etiology for cognitive impairment [6,7] and thus 
regulating the activities of AChE has become a crucial research focus [8].
Synthetic acetyl-cholinesterase inhibitors (AChEIs) include donepezil, 
rivastigmine, galantamine, and tacrine are commercially available 
drugs which influence the dynamics of ACh by inhibiting the activity 
of AChE. These actions taken place on cholinergic receptors of synaptic 
cells. Due to the side effects of synthetic AChEIs which include 
gastrointestinal disturbances, moderate effectiveness, high cost and 
short half-life of AChEIs, there always a need for exploring the character 
for newer potent and long-lasting AChE inhibitors with minimal side 
effects [9-11]. There always a need for exploring the character for newer 
potent and long-lasting AChE inhibitors with minimal side effects. An 
outsized number of plant species from different parts of the globe are 
examined for cholinesterase inhibitory activity [8,12].
Traditional medicine is defined as the sum total of the knowledge, 
skill, and practices based on the theories, beliefs, and experiences 
indigenous to different cultures, whether explicable or not, used in 
the maintenance of health as well as in the prevention, diagnosis, 
improvement, or treatment of physical and mental illness [13]. Siddha 
system is one of the traditional systems of medicine mainly practiced 
in Southern India. This is a standard system of drugs mainly practiced 
within the southern a part of India. As per Siddha literature, Muthu 
Parpam is the herbo - marine Siddha formulation which has the 
indication for Marutchi (i.e., confusion and perplexity of mind). Muthu 
(Pearl) is one in all the nine gems possess the expectorant, styptic, 
tonic, and spasmodic action [14,15]. Hence, this study was an attempt 
to find out the ACh esterase (AChE) inhibition potential of Muthu 
Parpam.
METHODS
The purification process of Muthu [14]
Soak the pearl (35 g) in sour curd and should be kept under the sunlight 
for 3 days. Daily morning sour curd should be poured on the pearl. To 
stay dry, it should be kept under the daylight for 2 days without adding 
the curd. Repeat this process 2 times and then a pearl should be washed 
and dry it.
Ingredients [14]
•	 Purified Muthu (Pinctada margaritifera) – 1 palam (35 g)
•	 Notchi (Vitex negundo) – 2 palam (70 g)
•	 Nilappanai kizhangu (Curculigo orchioides) – 2 palam (70 g).
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Method of preparation
Thirty-five grams of purified Muthu (pearl) should be soaked in 70 g of 
notchi juice for 2 days and then grind it with the notchi juice for 2 days. Then, 
it should be made into villai (pellets) and dry it in the sunlight. The pellets 
should be placed in an earthen vessel which should be closed with another 
vessel and the margin of vessels sealed with seven layered clay cloths and 
the set up should be dried in sunlight for 1 day. After that, it should be placed 
in a deep pit and pudam process (calcination process) should be done with 
40 cow dung cakes. Then, this same procedure should be repeated with the 
juice of nilappanai kizhangu and then make it as a fine powder. The final 
product, the parpam should be stored in the airtight glass container.
Indication and adjuvants [16]
•	 Nirvidam (Asparagus racemosa) [15] – Nithiraiyil undaagum 
marutchi (Confusion and perplexity of mind during the sleep)
•	 Water – Maalaikan noi (Night blindness)
•	 Milk – Pithathaal undaagum veppam (Heat due to pitham)
•	 Nilathulasi juice – valippu (epilepsy)
•	 Nilavilaa juice – pitha diseases
•	 Devadhaaru decoction – Vatha diseases
•	 Butter – moolam (Piles)
•	 Vilvam leaf juice – Adhisaaram (diarrhoea)
•	 Brown sugar – vaanthi (Vomit).
Test drug for analysis
The test drug Muthu Parpam prepared with the above manner was 
procured from the GMP certified pharmaceutical (Earth India Naturals) 
company and given for the analysis.
In vitro AChE enzyme inhibition assay – methodology [17]
AChE activity was measured employing a modified 96-well microplate 
assay supported Ellman’s method. Enzyme hydrolyses the substrate 
acetylthiocholine leading to the merchandise thiocholine which 
reacts with Ellman’s reagent (DTNB) to provide 2-nitrobenzoate-
5-mercaptothiocholine and 5-thio-2-nitrobenzoate which might 
be detected at 412 nm. 50 mM Tris–HCl pH 8.0 was used as a buffer 
throughout the experiment. AChE enzyme stock solution (518 U/ml) 
was stored at ‒80°C and therefore, the enzyme-dilution was done in 
0.1% BSA within the buffer. DTNB was dissolved within the buffer 
containing 0.1 M NaCl and 0.02 M MgCl2. ATCI was dissolved in 
deionized water. Within the 96-well plates, 100 µl of three mM DTNB, 
20 µl of 0.26 U/ml of AChE, and 40 µl of buffer (50 mM tris pH 8.0), to 
which 20 µl of test drug in various concentrations (25, 50, 100, 250, 
and 500 µg/ml) dissolved in a buffer containing no more than 10% 
methanol was added to the wells. After mixing, the plate was incubated 
for 15 min (25°C). The enzymatic reaction was initiated by the addition 
of 20 µl of 15 mM acetylthiocholine iodide and therefore the hydrolysis 
of acetylthiocholine was monitored by reading the absorbance every 
5 min for 20 min at 412 nm. Physostigmine (5, 10, 20, and 40 µg/ml) was 
used because of the positive control. All the reactions were performed 
in triplicate.
RESULTS AND DISCUSSION
AChE activity has been shown to be increased within and around 
amyloid plaques to develop the assembly of amyloid beta-peptides 
into fibrils and to extend the cytotoxicity of those peptides. The results 
obtained from the four extracts of Muthu Parpam against AChE enzyme 
inhibition activity and also the percentage inhibition was evaluated 
and tabulated (Tables 1 and 2). Muthu parpam showed very potent 
inhibition (71.68 ± 2.38%) at the concentration of 500 µg/ml in 
comparison with physostigmine (84.87 ± 4.78%) at the concentration 
of 40 µg/ml (Graph 1).
Physostigmine was first isolated from Calabar beans (Physostigma 
venenosum) in 1864 [18] and is an AChE inhibitor [19]. Although 
physostigmine can cross the blood brain barrier, this drug contains 
a narrow therapeutic index due to its short half-life and various side 
effects. The common side effects of physostigmine are hypersalivation, 
nausea, vomiting, and arrhythmia in arterial blood vessel patient and 
bradycardia [20]. Some studies have suggested that the AChE inhibitor, 
rivastigmine could also be fatal [21], while cholinesterase inhibitors 
Table 2: Percentage inhibition of AChE enzyme by standard drug
The concentration of 
physostigmine in µg/ml
Percentage inhibition of AChE 





Each value represents the mean±SD. n=3
Table 1: Percentage inhibition of AChE enzyme by test drug - MP
The concentration of MP 
in µg/ml
Percentage inhibition of AChE 






Each value represents the mean±SD. n=3. MP: Muthu Parpam
Graph 1: Percentage inhibition of standard - physostigmine on 
AChE enzyme inhibition assay
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remain to be a vital therapeutic tool against AD. AChE inhibitors in 
contemporary medicines should be undertaken for the treatment to 
prevent the side effects.
This study revealed that the Muthu Parpam significantly inhibited AChE 
in a very dose-dependent manner. Notchi (V. negundo) juice employed 
in the preparation of Muthu Parpam has the pharmacological activity 
of anxiolytic and anti-amnesic [22,23]. Some pharmacological studies 
are reported that the Nilappanai kizhangu (C. orchioides) have the 
anticonvulsant activity and alleviate the cerebral ischemic injury in 
in vivo and in vitro experimental models [23,24]. Hence, adding these 
juices additionally enhance the cognitive function of the brain.
CONCLUSION
Aging is a natural and normal process; it is decaying the body 
continuously. Inappropriate aging may be preventable through 
principles suggested by ancient sages (Siddhars) which are called as 
Noianugavidhi (prevention of diseases). Promoting mental health 
state is that the need of the hour. Effectiveness of Muthu Parpam in 
the treatment of AD was proven through this study on the inhibition 
potential of acetylcholine choline esterase. It had been a preliminary 
screening for evaluating the efficacy. Hence, further clinical studies on 
Muthu Parpam should be necessary to position the footprints within 
the neurocognitive field.
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